The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
- Alzheimer Disease
- Psychomotor Agitation
- Caregiver Burden
- Aggression
- Marijuana Abuse
- Dementia
- Depression
- Anxiety Disorders
Age: 60 years - 66+
Gender: All